ABBV vs CAPR

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Capricor Therapeutics (CAPR) maintains its high-risk, high-reward profile, with its valuation hinging primarily on the upcoming FDA PDUFA date of August 22, 2026, for Deramiocel in Duchenne Muscular Dystrophy (DMD). The multi-billion dollar TAM and Deramiocel’s unique cell therapy mechanism offer substantial 10x growth potential if approved. Despite a strong cash position of $278.6 million providi...